Cannabinoids and Psoriasis: Early Evidence Points to Possible Symptom Relief
Psoriasis is a chronic, immune-mediated disease that causes inflamed, scaly patches on the skin. It affects millions of people worldwide and can also involve the nails, scalp, and joints. Although treatments can control the disease, there is currently no cure.
Interest in cannabis-derived compounds—particularly cannabidiol (CBD)—has grown as researchers investigate new ways to reduce inflammation, scaling, itching, and pain. But the evidence remains limited, and cannabinoid products should not be considered established replacements for standard psoriasis treatment.
The strongest psoriasis-specific evidence so far comes from a 2022 randomized, double-blind, placebo-controlled study conducted in Thailand. Researchers assigned 51 people with mild plaque psoriasis to apply a 2.5% CBD ointment and a placebo to matched plaques on different sides of the body for 12 weeks. The CBD-treated lesions had a modest but statistically significant reduction in local psoriasis severity, particularly scaling. Some lesions also showed greater area reduction than those treated with placebo.
However, the study was small, focused on mild plaque psoriasis, and evaluated selected lesions rather than overall disease across the body. Six participants developed irritation on both sides and discontinued treatment, although the irritation resolved within a week. The findings are encouraging, but they do not establish that CBD can control moderate or severe psoriasis, prevent flares, or replace prescription therapies.
Other studies cited in discussions of cannabinoids and psoriasis provide useful clues but are less direct. A 2019 retrospective report of 20 people included only five patients with psoriasis and found improvements after three months of using a CBD-enriched ointment. Because the study was anecdotal, retrospective, and lacked a control group, its results cannot determine whether CBD caused the improvement. The study is available through PubMed.
A 2020 trial of a shampoo containing 0.075% broad-spectrum CBD included 50 people with either mild-to-moderate scalp psoriasis or seborrheic dermatitis. Participants reported less itching, burning, redness, and scaling after two weeks, and the product was generally well tolerated. The results, published in Skin Appendage Disorders, are relevant to scalp symptoms but cannot show that CBD treats psoriasis throughout the body. The study also had a short follow-up period and did not provide the same level of evidence as a large, long-term controlled trial.
Several other investigations often mentioned in connection with psoriasis do not actually test psoriasis treatment. For example, a 2015 study of a 3% cannabis-seed extract cream measured sebum and redness in the cheeks of 11 healthy men, with acne and seborrhea—not psoriasis—as the proposed applications. Similarly, a 2020 open-label study of topical cannabis-based medicines involved painful calciphylaxis leg ulcers, a separate and uncommon wound condition. These studies may contribute to understanding how cannabinoid-containing products affect skin, but their findings should not be presented as proof of effectiveness against psoriasis.
The biological rationale for studying cannabinoids comes partly from the skin’s endocannabinoid system. This network includes naturally occurring signaling molecules, cannabinoid receptors, and enzymes involved in regulating processes such as cell growth, inflammation, immune activity, and skin-barrier function. A 2009 review of the endocannabinoid system in skin health and disease proposed that these pathways might eventually be targeted in conditions involving excessive skin-cell growth, including psoriasis. That mechanism is a research hypothesis, not evidence that over-the-counter cannabis products are clinically effective.
More recent evidence also argues for caution. In a small randomized trial published online in December 2025, 28 people with chronic plaque psoriasis received either 60 milligrams of oral CBD daily or placebo alongside standard care. CBD did not significantly improve overall psoriasis severity, measured by the Psoriasis Area and Severity Index, although participants reported temporary improvements in itching and sleep onset. The results, reported in PubMed, suggest that possible symptom benefits may not translate into meaningful reduction of the underlying disease.
For now, cannabinoid products are best viewed as experimental or supportive options rather than primary psoriasis therapies. The American Academy of Dermatology’s psoriasis treatment guidelines emphasize established topical medicines, phototherapy, and systemic treatments, depending on disease severity and location. Psoriasis affecting sensitive areas such as the genitals, palms, soles, or skin folds may require particularly careful treatment, and generalized pustular or erythrodermic psoriasis needs prompt medical evaluation.
Safety is another consideration. CBD products sold without a prescription may contain different amounts of CBD than their labels indicate and may be contaminated or contain THC. CBD can also cause side effects and interact with medications, including some drugs that affect the liver. The National Center for Complementary and Integrative Health advises consumers to discuss cannabinoid use with a healthcare professional.
Overall, early clinical research suggests that topical CBD may modestly improve scaling or irritation in some people with mild psoriasis, especially on the scalp or in limited plaques. The evidence is still based on small studies, short follow-up periods, and different formulations. Larger, well-controlled trials are needed before cannabinoids can be considered a reliable treatment for psoriasis.
